Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zelda Therapeutics has reached 103 research participants in its Autism Observational Study
  • The study is researching the effects of medicinal hemp products in children with autism
  • Analysis has identified doses and formulations of cannabis that improve behaviour, anxiety, sleep, irritability and hyperactivity
  • The first study will identify the marked differences in CBD and THC usage profiles

Zelda Therapeutics has successfully enrolled its 100th research participant in its Autism Observational Study.

Zelda is an Australian-based biopharmaceutical company developing a range of cannabinoid-based formulations.

The observational study is being conducted at the Children’s Hospital of Philadelphia (CHOP).

It is seeking to use parent-reported data to better understand the effects of medicinal hemp products in children with autism.

This study marks the first to combine a comprehensive panel of key efficacy, pharmacological and safety read-outs with a community-based real-world assessment of hemp usage in children with autism.

There are 103 participants currently enrolled in the study. Zelda hopes to reach its final target of 150 by early 2020.

The 103 participants were using 76 different medicinal cannabis products, with over 42 per cent using multiple products simultaneously.

Analysis of these cannabinoid formulations showed an improvement in anxiety levels, sleep, irritability and hyperactivity. The extent of the improvement, however, was dependent on whether the cannabinoids were THC-only based, CBD-only based or combinations of both.

“Results show that treatments with a range of cannabis medicines were associated with improvements in several key behavioural markers that are prominent in children diagnosed with autism,” Managing Director Dr Richard Hopkins said.

“While these initial findings are encouraging, we need to be cautious interpreting the results from observational studies such as ours, where parent-reported data is used and where there is limited baseline information available prior to treatment, which can result in significant bias,” he stated.

Zelda believes it’s in a good position in the sector as the demand for prescription cannabis products increases.

The company is planning a randomised blinded clinical trial for children with autism as well as treatment options for later this year.

ZLD by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.